Black Diamond Therapeutics (NASDAQ:BDTX) Issues Quarterly Earnings Results

Black Diamond Therapeutics (NASDAQ:BDTX) released its quarterly earnings data on Sunday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02, MarketWatch Earnings reports.

Shares of NASDAQ:BDTX opened at $33.07 on Monday. The business’s fifty day moving average price is $31.91 and its two-hundred day moving average price is $33.98. Black Diamond Therapeutics has a fifty-two week low of $17.63 and a fifty-two week high of $46.25. The stock has a market capitalization of $1.23 billion and a price-to-earnings ratio of -5.47.

In other Black Diamond Therapeutics news, Director Bradley J. Phd Bolzon sold 18,090 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $33.26, for a total value of $601,673.40. Following the sale, the director now directly owns 8,729 shares in the company, valued at $290,326.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Versant Venture Capital Vi, L. sold 15,980 shares of the business’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $33.26, for a total value of $531,494.80. The disclosure for this sale can be found here. Insiders sold 217,471 shares of company stock worth $7,175,068 over the last quarter.

A number of analysts have recently issued reports on the company. BidaskClub upgraded Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 26th. Zacks Investment Research upgraded Black Diamond Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research report on Wednesday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $53.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Black Diamond Therapeutics currently has an average rating of “Buy” and a consensus price target of $45.60.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.

See Also: What are gap-down stocks?

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.